@article{0347d874c2b6473a9fcccb65b5ab75e8,
title = "Establishment of a piglet model for peritoneal metastasis of ovarian cancer",
abstract = "Background: A piglet model for peritoneal metastasis (PM) of ovarian cancer was developed. It will contribute to establishing innovative chemotherapeutical and surgical strategies without any limitation on rodent models. Methods: A total of 12 four- to five-week-old piglets of 7 to 8 kg were used. Two phases of ovarian cancer cell injections were performed with laparoscopic surgery. In phase I trial, 5.0 × 106 SK-OV-3 cells in 0.1 ml suspension were inoculated into the omentum, peritoneum, and uterine horns of two piglets twice with a one-week interval. In the phase II trial, 5.0 × 106 SNU-008 cells in 0.1 ml suspension were injected only into uterine horns within the same time frame because tumor implantation after inoculation of SK-OV-3 cells was not observed at the omentum or peritoneum in the phase I trial. Modified peritoneal cancer index (PCI) score was used to monitor tumorigenesis up to 4 weeks after inoculation. Tumor tissues disseminated in the peritoneum 4 weeks after injection were used for histological examination with hematoxylin and eosin (H&E) and paired-box gene 8 (PAX-8) staining. Results: In the phase I trial, two piglets showed PM with modified PCI scores of 5 and 4 at 3 weeks after the first inoculation, which increased to 14 and 15 after 4 weeks, respectively. In the phase II trial, PM was detected in eight of ten piglets, which showed modified PCI scores of 6 to 12 at 4 weeks after the first inoculation. The overall incidence of PM from the total of 12 piglets after inoculation was 75%. Immunohistochemical H&E and PAX-8 staining confirmed metastatic tumors. Conclusions: This study provides strong evidence that piglets can be employed as a model for PM by inoculating ovarian cancer cell lines from humans. Using two cell lines, the PM rate is 75%.",
keywords = "Immunocompetent, Large animal model, Peritoneal metastasis, Piglet, Uterine horn",
author = "{the KoRIA Trial Group} and Lee, {Eun Ji} and Park, {Soo Jin} and Aeran Seol and Hyunji Lim and Sumin Park and Ahn, {Ji Yeon} and Lim, {Jeong Mook} and Kim, {Hee Seung} and Park, {Ji Won} and Gwonhwa Song and Jiyen Ham and Sunwoo Park and Yim, {Ga Won} and Shim, {Seung Hyuk} and Kang, {Beong Cheol} and Chang, {Suk Joon} and Whasun Lim and Lee, {Jung Chan}",
note = "Funding Information: We deeply appreciate Dreampac Corp. (Ganwon, South Korea), Precision Medicine for Peritoneal Metastasis Corp. (Ganwon, South Korea), Samyang Biopharmaceuticals Corp., and KARL STORZ Endoscopy Korea CO., Ltd. for collaborative work. Moreover, we thank to all members of the KOrean Rotational Intraperitoneal pressurized Aerosol Chemotherapy (KoRIA) trial group, including Ji Won Park (Department of Surgery, Seoul National University Hospital), Gwonhwa Song, Jiyen Ham(Institute of Animal Molecular Biotechnology and Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University), Sunwoo Park (Department of Plant & Biomaterials science, Gyeongsang National University), Ga Won Yim (Department of Obstetrics and Gynecology, Dongguk University College of Medicine), Seung-Hyuk Shim (Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine), Beong-Cheol Kang (Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital), Suk Joon Chang (Department of Obstetrics and Gynecology, Ajou University School of Medicine), Whasun Lim (Department of Biological Sciences, Sungkyunkwan University), Jung Chan Lee (Department of Biomedical Engineering, Seoul National University College of Medicine). EJL, SJP, JYA, JML, and HSK have a patent entitled “A Method for Preparing a Large Animal Model with Peritoneal Carcinomatosis” (Patent No. 10-2019-0100793, South Korea; 16/846,321, USA). Funding Information: This research was supported by a grant from Seoul National University (No, 800–20190437). Moreover, Commercializations Promotion Agency for R&D Outcomes supported this research with a grant funded by the Korea government (the Ministry of Science and ICT; No. 1711151316). Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1186/s12967-022-03533-1",
language = "English",
volume = "20",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",
}